Full coverage· Health· Updated
FDA Approves Revolutionary Pancreatic Cancer Drug Boosting Revolution Medicines' Valuation
The FDA approved Rasonque, a new drug by Revolution Medicines, for metastatic pancreatic cancer, doubling patient survival and boosting the company’s valuation to $46 billion. The drug uniquely targets the RAS protein and showed unprecedented clinical results, leading to early approval.
6 newsrooms · 1 language · since
Plus
What happened
- 01FDA approves Rasonque for metastatic pancreatic cancer, doubling patient survival to 13.2 months.
- 02Revolution Medicines’ stock surged 477% in a year, valuing the company at $46 billion.
- 03Rasonque targets the RAS protein, a key driver in 90%-95% of pancreatic cancers.
- 04The drug was approved based on a 500-patient trial with fewer side effects than chemotherapy.
- 05Merck’s $28-$32 billion acquisition attempt of Revolution Medicines failed over pricing.
- 06Other pharma giants and Israeli firms are developing RAS-targeting cancer therapies.
Revolution Medicines is exploring broader uses and faces competition from major pharma firms developing similar therapies.
The coverage
6 newsrooms on this story
Who covered it
- LeftNone
- Centre2
- Right2
- Haredi1
- ArabNone
- Other1
How it broke
See which of the 6 newsrooms broke it, and who waited